{"adverse_reactions":["6. ADVERSE REACTIONS 6.1. The most common mild adverse reaction is slight reddening at the injection site due to the mechanical effect of the needle or a superficial skin reaction of mild erythema."],"clinical_pharmacology":["12. CLINICAL PHARMACOLOGY 12.1. Mechanism of Action The medication acts through a low-dose enzymatic mechanism. 12.2. Pharmacodynamics The physiological effects of OMEOFORMULA®1- ADIPOSITY is are due to the effects of the ingredients according to their description in the Homeopathic Materia Medica. 12.3. Pharmacokinetics Homeopathic attenuation provides complete bioavability of the active ingredients."],"clinical_studies":["14. CLINICAL STUDIES 14.1. OMEOFORMULA®1-ADIPOSITY formulation is based on classical Homeopathy and each ingredient has been selected according to the homeopathic description as refer in Materia Medica."],"contraindications":["4. CONTRAINDICATIONS 4.1. There is no history of hypersensitivity to OMEOFORMULA®1-ADIPOSITY. However patients with a known hypersensitivity to any ingredient should be tested before use. Make a spot injection (0.1ml) into the forearm and observe for any reactions for 1 hour."],"description":["11. DESCRIPTION OMEOFORMULA®1- ADIPOSITY is a sterile solution made with isotonic sodium chloride solution. OMEOFORMULA®1-ADIPOSITY formulation is based on classical Homeopathy and each ingredient has been selected according to the homeopathic description as referred to in Materia Medica • Fucus vesiculosus and Thyroidinum improve oxidative metabolic processes. Hypophysis and Adeps suillus enhance immune response against adiposities. Sulfur, Carduus marianus, and Sarsaparilla permits the centrifugation of the connective tissue toxins, the hepatic catabolism of fats, and activation of renal activity; • Artery, and Calcarea fluorica act on tissue tonification by stimulating increased vascularisation, combating exhaustion of the matrix. The Krebs cycle intermediates provide general stimulation of the cell emphasizing triglyceride hydrolysis (Fumaric acid), drainage (Malic acid) and support of connective tissue structure (alpa Keto- glutaric acid)."],"dosage_and_administration":["2. DOSAGE AND ADMINISTRATION 2.1. Treatment of total body adiposity for IM application: 1 vial 1-3 times a week according to severity and clinic evolution. 2.2. Treatment of localized adiposity using mesotherapy technique: Apply 0,3 ml for each point. Using a 13 mm, 30G or a 4 mm, 27G needle, make the classic intradermal injections utilizing mesotherapy technique. Application points: Apply to the affected area (abdomen, lower and upper limbs, gluteus muscles)or at acupuncture points. Standard protocol consists of one session a week for 5-7 weeks. For prolonged treatments, 2 sessions for the first week, 1 session a week for 1 month and then 1 session a month are recommended. Discard unused solution. 2.3. Opening of Vials: Use sterile needles and sterile syringe. Do not reuse. Do not use if foreign particles are present. Draw 1 cc of air into syringe, insert needle into vial inject air and withdraw the solution into the syringe."],"dosage_forms_and_strengths":["3. DOSAGE FORMS AND STRENGTHS 3.1. Injectable solution for subcutaneneous, intradermal, or intramuscular administration. Pharmaceutical form: 2 ml glass vials. 3.2. Each ingredient is attenuated according to the Homeopathic Pharmacopeia of United States. Active ingredients : a-Ketoglutaricum acidum 6X; Adeps suillus 10X; Artery 6X; Barium oxalosuccinate 6X; Calcarea fluorica 10X; Calcarea fluorica 30X; Calcarea fluorica 200X; Carduus marianus 6X; Cis-Aconitic acid 6X; Citricum acidum 6X; DL malic acid 6X; Fucus vesiculosus 10X; Fucus vesiculosus 30X; Fucus vesiculosus 200X; Fumaricum acidum 6X; Hypophysis 10X; Hypophysis 30X; Hypophysis 200X; Magnesium gluconate 6X; Manganum phosphoricum 6X; Natrum oxalaceticum 6X; Natrum pyruvicum 6X; Nicotinamidum 6X; Sarsaparilla 6X; Succinicum acidum 6X; Sulphur 12X; Thyroidinum 10X. Inactive ingredient : Sterile isotonic sodium chloride solution."],"drug_abuse_and_dependence":["9. DRUG ABUSE AND DEPENDENCE 9.1. No Known."],"drug_interactions":["7. DRUG INTERACTIONS 7.1. None Known."],"effective_time":"20110627","id":"46a23fff-44b6-4005-895b-ab08c1da50f3","indications_and_usage":["1. INDICATIONS AND USAGE 1.1. Treatment of total body adiposity 1.2. Treatment of localized adiposity It is helpful to combine the treatment with oral detoxification therapy, in order to facilitate the elimination of the toxic load, activated by the injection therapy. Patients should also incorporate dietary modifications to facilitate weight loss."],"information_for_patients":["17. PATIENT COUNSELING INFORMATION 17.1. Patients should be informed of the homeopathic approach and OMEOFORMULA®1-ADIPOSITY therapeutic goals."],"nonclinical_toxicology":["13. NONCLINICAL TOXICOLOGY 13.1. OMEOFORMULA®1-ADIPOSITY has no level of toxicity due to the attenuation of the ingredients."],"openfda":{},"overdosage":["10. OVERDOSAGE 10.1. No Known."],"package_label_principal_display_panel":["PACKAGE LABEL image of box label"],"references":["15. REFERENCES 15.1. E.Italia, M. De Bellis: Manuale di Omeo-mesoterapia – Guna Ed. 1995. 15.2. H.H.Reckeweg: Homeopathic Materia Medica omeopatica. Aurelia Verlag."],"set_id":"9d9db50d-d8a2-4ce7-b2ff-66c11eeb4c49","spl_product_data_elements":["OMEOFORMULA1-ADIPOSITY .ALPHA.-KETOGLUTARIC ACID - ACONITIC ACID, CIS - BARIUM CATION - CALCIUM FLUORIDE - CITRIC ACID MONOHYDRATE - FUCUS VESICULOSUS - FUMARIC ACID - LARD - MAGNESIUM GLUCONATE - MALIC ACID - MANGANESE PHOSPHATE, DIBASIC - NIACINAMIDE - SARSAPARILLA - SILYBUM MARIANUM SEED - SODIUM DIETHYL OXALACETATE - SODIUM PYRUVATE - SUCCINIC ACID - SULFUR - SUS SCROFA ARTERY - SUS SCROFA PITUITARY GLAND - THYROID - LARD LARD .ALPHA.-KETOGLUTARIC ACID .ALPHA.-KETOGLUTARIC ACID SUS SCROFA ARTERY SUS SCROFA ARTERY BARIUM OXALOSUCCINATE BARIUM OXALOSUCCINATE CALCIUM FLUORIDE CALCIUM FLUORIDE SILYBUM MARIANUM SEED SILYBUM MARIANUM SEED ACONITIC ACID, (Z)- ACONITIC ACID, (Z)- CITRIC ACID MONOHYDRATE ANHYDROUS CITRIC ACID MALIC ACID MALIC ACID FUCUS VESICULOSUS FUCUS VESICULOSUS FUMARIC ACID FUMARIC ACID SUS SCROFA PITUITARY GLAND SUS SCROFA PITUITARY GLAND MAGNESIUM GLUCONATE MAGNESIUM CATION MANGANESE PHOSPHATE, DIBASIC MANGANESE PHOSPHATE, DIBASIC SODIUM DIETHYL OXALACETATE DIETHYL OXALACETATE SODIUM PYRUVATE PYRUVIC ACID NIACINAMIDE NIACINAMIDE SMILAX REGELII ROOT SMILAX REGELII ROOT SUCCINIC ACID SUCCINIC ACID SULFUR SULFUR THYROID THYROID SODIUM CHLORIDE WATER"],"storage_and_handling":["16. HOW SUPPLIED/STORAGE AND HANDLING 16.1. NDC 17089-272-31 10 glass vials packed in carton box 16.2. NDC 17089-272-32 50 glass vials packed in carton box 16.3. Store at room temperature, 20-25°C (68-77° F). Avoid freezing and excessive heat."],"use_in_specific_populations":["8. USE IN SPECIFIC POPULATIONS 8.1 Pregnancy : Pregnancy category C. Animal reproduction studies have not been conducted with OMEOFORMULA®1-ADIPOSITY. OMEOFORMULA®1-ADIPOSITY should not be administered to a pregnant woman. 8.2 Nursing mothers : It is not known whether any of the ingredients in OMEOFORMULA®1-ADIPOSITY are secreted in human milk. However, since many drugs are secreted in human milk, caution should be exercised when OMEOFORMULA®1-ADIPOSITY is administered to a nursing woman. 8.3 Pediatric use : OMEOFORMULA®1-ADIPOSITY is safe to use in adults 14 years and older. 8.4 Geriatric use : No restrictions."],"version":"3","warnings_and_cautions":["5. WARNINGS AND PRECAUTIONS 5.1. Be sure to disinfect the area before application. Skin disinfection helps avoid infection at the site of administration that can result from saprophytic bacteria (i.e. atypical mycobacteria, staphylococcus genus) that may be present on the skin. 5.2. Skin disinfection is required before application. Saprophytic bacteria may produce injection site abscesses with improper skin preparation."]}